


**PRODUCT: BX-517**

|                           |   |
|---------------------------|---|
| <b>ALTERNATE NAMES:</b>   | BX 517; BX517; PDK1 inhibitor2; (Z)-N-(3-(1-(1H-pyrrol-2-yl)ethylidene)-2-hydroxy-3H-indol-5-yl)carbamimidic acid; [(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea  |
| <b>CATALOG#:</b>          | B1764-5, -25  |
| <b>AMOUNT:</b>            | 5 mg, 25 mg   |
| <b>STRUCTURE:</b>         |    |
| <b>MOLECULAR FORMULA:</b> | C <sub>15</sub> H <sub>14</sub> N <sub>4</sub> O <sub>2</sub>   |
| <b>MOLECULAR WEIGHT:</b>  | 282.3   |
| <b>CAS NUMBER:</b>        | 850717-64-5   |
| <b>APPEARANCE:</b>        | Solid powder  |
| <b>SOLUBILITY:</b>        | DMSO  |
| <b>PURITY:</b>            | >98%  |
| <b>STORAGE:</b>           | Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.  |
| <b>DESCRIPTION:</b>       | BX-517, also known as PDK1 inhibitor2, is a potent and selective PDK1 inhibitor that binds to the ATP binding pocket.   |
| <b>REFERENCES:</b>        | <ol style="list-style-type: none"><li>Islam I et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8.</li><li>Islam I et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3819-25.</li></ol> |
| <b>HANDLING:</b>          | Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.   |

**RELATED PRODUCTS:**

- APY-0201 (Cat. No. 9564-5, 25)
- AS-604850 (Cat. No. 2339-1, 5)
- BAG956 (Cat.No. 2456-5, 25)
- BAY 80-6946 (Cat. No. B1267-5, 25)
- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- CAL-101 (Cat. No. 2613-5, 25)
- GDC-0941 bismesylate (Cat. No. 1623-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
- GDC-0941 (Cat. No. 1623-1, 5)
- GSK-263771 (Cat. No. 2793-5, 25)
- IC87114 (Cat. No. 1661-1)
- IPI-145 (Cat. No. 2445-5, 25)
- LY 294002 (Cat. No. 1667-5, 25)
- NVP-BKM120 (Cat. No. 2619-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1, 5)
- OSU-03012, hydrochloride (Cat. No. 2295-5, 25) P
- I-103 (Cat. No. 1728-1, 5)
- PIK-294 (Cat. No. 2614-5, 25)
- PI3-Ky Inhibitor, AS-605240 (Cat. No. 1780-1, 5)
- PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
- PP242 (Cat. No. 1658-1)
- PX-866 (Cat. No. 1965-1, 5)
- Rapamycin (Cat. No. 1568-5, 50)
- SAR260301 (Cat. No. B1263-5, 25)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1, 5)
- Wortmannin (Cat. No. 1670-1)
- YM201636 (Cat. No. 2045-1, 5)
- XL147 (Cat. No. 9401-5, 25)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*